AR039547A1 - Terapia de reemplazo hormonal - Google Patents

Terapia de reemplazo hormonal

Info

Publication number
AR039547A1
AR039547A1 ARP030101719A ARP030101719A AR039547A1 AR 039547 A1 AR039547 A1 AR 039547A1 AR P030101719 A ARP030101719 A AR P030101719A AR P030101719 A ARP030101719 A AR P030101719A AR 039547 A1 AR039547 A1 AR 039547A1
Authority
AR
Argentina
Prior art keywords
days
treatment cycle
menopausal
phase
replacement therapy
Prior art date
Application number
ARP030101719A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR039547A1 publication Critical patent/AR039547A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Métodos destinados a proporcionar terapia de reemplazo hormonal a mujeres perimenopáusicas, menopáusicas y posmenopáusicas mediante la administración secuencial de combinaciones de estrógenos conjugados y trimegestona. Reivindicación 1: Un método para el tratamiento o la inhibición de trastornos menopáusicos o posmenopáusicos en una mujer perimenopáusica, menopáusica o posmenopáusica que lo necesita, que comprende proporcionar oralmente a dicha mujer, en forma continua y sin interrupciones durante 28 días en un ciclo de tratamiento de 28 días, una primera fase de una posología diaria de 0,1 a 0,45 mg de estrógenos conjugados, en la que se proporciona la misma posología de estrógenos conjugados por 10-18 días del ciclo de tratamiento, empezando el día 1 del ciclo de tratamiento y una segunda fase de una combinación de una posología diaria de 0,1 a 0,45 mg de estrógenos conjugados y 0,005 a 0,25 mg de trimegestona, en la que se proporciona la misma posología de la combinación por 10-18 días del ciclo de tratamiento, empezando el día siguiente al término de la primera fase.
ARP030101719A 2002-05-17 2003-05-16 Terapia de reemplazo hormonal AR039547A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38134802P 2002-05-17 2002-05-17

Publications (1)

Publication Number Publication Date
AR039547A1 true AR039547A1 (es) 2005-02-23

Family

ID=29584308

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101719A AR039547A1 (es) 2002-05-17 2003-05-16 Terapia de reemplazo hormonal

Country Status (11)

Country Link
US (1) US20030216368A1 (es)
EP (1) EP1505982A1 (es)
JP (1) JP2005530790A (es)
CN (1) CN1668309A (es)
AR (1) AR039547A1 (es)
AU (1) AU2003234574A1 (es)
BR (1) BR0311184A (es)
CA (1) CA2483770A1 (es)
MX (1) MXPA04011257A (es)
TW (1) TW200404551A (es)
WO (1) WO2003097069A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
KR101275198B1 (ko) 2005-05-23 2013-06-18 엘지전자 주식회사 드럼세탁기 및 그에 적용되는 드럼 제조방법
EP2289487A1 (en) * 2005-12-27 2011-03-02 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
CA2654152A1 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
US20100022497A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
US20100022494A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100022991A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and device for maintaining physiological levels of steroid hormone in a subject

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
AU3961697A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Oral contraceptive
US6451778B1 (en) * 1996-07-26 2002-09-17 Wyeth Oral contraceptive
WO2000041700A1 (en) * 1999-01-18 2000-07-20 Novo Nordisk A/S Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders
AU2092200A (en) * 1999-01-18 2000-08-01 Novo Nordisk A/S Use of estrogens and delta-gonadien-21-ol-3,20-diones
CA2267743C (en) * 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
KR20040037097A (ko) * 2001-09-29 2004-05-04 솔베이 파머슈티컬스 게엠베하 에스트로겐/게스타겐 조합 제제 및 그 이용

Also Published As

Publication number Publication date
MXPA04011257A (es) 2005-01-25
JP2005530790A (ja) 2005-10-13
EP1505982A1 (en) 2005-02-16
WO2003097069A1 (en) 2003-11-27
TW200404551A (en) 2004-04-01
AU2003234574A1 (en) 2003-12-02
CN1668309A (zh) 2005-09-14
CA2483770A1 (en) 2003-11-27
BR0311184A (pt) 2005-02-22
US20030216368A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
EA200201000A1 (ru) Гормон-заместительная терапия
AR024566A1 (es) Administracion de esteroides androgenicos no orales a mujeres
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
AR051931A1 (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclos extendidos con dosis ascendentes
US20060254597A1 (en) Method of treatment of atrophic vaginitis by topical clitoral menthol or a related cooling compound
ECSP088123A (es) Anticoncepcion oral con trimegestona
AR048722A1 (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
AR039546A1 (es) Terapia de reemplazo hormonal
NZ514574A (en) Novel method of treatment
PE20070329A1 (es) Composiciones con estrogenos y metodos terapeuticos para su uso
BRPI0412493A (pt) métodos de tratamento hormonal utilizando regimes contraceptivos com administração contìnua de estrogênio
NZ591627A (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
AR033042A1 (es) Terapia de reemplazo hormonal
AR039547A1 (es) Terapia de reemplazo hormonal
CA2431645A1 (en) Methods of treating hormonal deficiencies in women undergoing estrogen replacement therapy
HUP0301791A2 (hu) Eljárás klimaktériummal összefüggő rendellenességek kezelésére nőkben a menopauza alatt vagy után
CR8010A (es) Regimenes de contraceptivos transdermicos extendidos
RU2003105159A (ru) Способ лечения климактерических расстройств у женщин во время или после менопаузы
HUP9901360A2 (hu) Cimicifuga racemosa-ból származó extraktum alkalmazása
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
PE20060368A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
AR009113A1 (es) UN PRODUCTO ANTICONCEPTIVO PARA DETENER LA OVULACIoN EN MUJERES DURANTE SU PERIODO DE ACTIVIDAD OVÁRICA
AR049195A1 (es) Uso de una combinacion de etinilestradiol y acetato de clormadinona para la preparacion de un medicamento
AR029189A1 (es) Uso de un inhibidor de fosfodiesterasa 4 y un corticoesteroide antiinflamatorio en forma combinada, separadamente o separadamente secuencial para la preparacion de un medicamento
UY29861A1 (es) Uso de valerato de estradiol en combinación con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral

Legal Events

Date Code Title Description
FB Suspension of granting procedure